Biomaterials to Facilitate Delivery of RNA Agents in Bone Regeneration and Repair

被引:16
作者
Tsekoura, Eleni K. [1 ]
Bahadur, Remant K. C. [1 ]
Uludag, Hasan [1 ,2 ,3 ]
机构
[1] Univ Alberta, Fac Engn, Dept Chem & Mat Engn, Edmonton, AB T6G 2R3, Canada
[2] Univ Alberta, Fac Med & Dent, Dept Biomed Engn, Edmonton, AB T6G 2R3, Canada
[3] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2R3, Canada
来源
ACS BIOMATERIALS SCIENCE & ENGINEERING | 2017年 / 3卷 / 07期
关键词
microRNAs; bone rengeneration; RNA reagents; scaffold; carrier; MESENCHYMAL STEM-CELLS; REGULATES OSTEOGENIC DIFFERENTIATION; PROMOTES OSTEOBLAST DIFFERENTIATION; GENE DELIVERY; IN-VITRO; MORPHOGENETIC PROTEINS; GOLD NANOPARTICLES; NONVIRAL VECTORS; LOCAL-DELIVERY; CLINICAL-APPLICATIONS;
D O I
10.1021/acsbiomaterials.6b00387
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Bone healing after traumatic injuries or pathological diseases remains an important worldwide problem. In search of safer and more effective approaches to bone regeneration and repair, RNA-based therapeutic agents, specifically microRNAs (miRNAs) and short interfering RNA (siRNA), are beginning to be actively explored. In this review, we summarize current attempts to employ miRNAs and siRNAs in preclinical models of bone repair. We provide a summary of current limitations when attempting to utilize bioactive nucleic acids for therapeutic purposes and position the unique aspects of RNA reagents for clinical bone repair. Delivery strategies for RNA reagents are emphasized and nonviral carriers (biomaterial-based) employed to deliver such reagents are reviewed. Critical features of biomaterial carriers and various delivery technologies centered around nanoparticulate systems are highlighted. We conclude with the authors' perspectives on the future of the field, outlining main critical issues important to address as RNA reagents are explored for clinical applications.
引用
收藏
页码:1195 / 1206
页数:12
相关论文
共 134 条
[1]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[2]   Bone morphogenetic proteins and their antagonists: current and emerging clinical uses [J].
Ali, Imran H. A. ;
Brazil, Derek P. .
BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (15) :3620-3632
[3]   Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[4]  
Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
[5]   Gold nanoparticle-based gene delivery: promises and challenges [J].
Bahadur, Remant K. C. ;
Thapa, Bindu ;
Bhattarai, Narayan .
NANOTECHNOLOGY REVIEWS, 2014, 3 (03) :269-280
[6]  
Balmayor E. R., 2015, FRONT BIOENG BIOTECH, V3, P1
[7]  
Browne S, 2013, TISSUE ENG PT A, V19, P1491, DOI [10.1089/ten.tea.2012.0721, 10.1089/ten.TEA.2012.0721]
[8]   Bone grafting, orthopaedic biomaterials, and the clinical need for bone engineering [J].
Brydone, A. S. ;
Meek, D. ;
Maclaine, S. .
PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H-JOURNAL OF ENGINEERING IN MEDICINE, 2010, 224 (H12) :1329-1343
[9]   Prevalence, Complications, and Hospital Charges Associated With Use of Bone-Morphogenetic Proteins in Spinal Fusion Procedures [J].
Cahill, Kevin S. ;
Chi, John H. ;
Day, Arthur ;
Claus, Elizabeth B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (01) :58-66
[10]   RNA interference by nanofiber-based siRNA delivery system [J].
Cao, Haoqing ;
Jiang, Xu ;
Chai, Chou ;
Chew, Sing Yian .
JOURNAL OF CONTROLLED RELEASE, 2010, 144 (02) :203-212